Reference

Efficacy and safety of brimonidine, dorzolamide and latanoprost as adjunctive therapy in primary open angle glaucoma

Efficacy and safety of brimonidine, dorzolamide and latanoprost as adjunctive therapy in primary open angle glaucoma.Some chemicals with cas registry numbers like 59803-98-4 and 130209-82-4 are also used. Sodhi, P. K.; Pandey, R. M.; Ratan, S. K. (Department of Ophthalmology, Safdarjung Hospital, New Delhi, India). International Journal of Clinical Practice, 57(10), 875-878 (English) 2003 Blackwell Publishing Ltd. CODEN: IJCPF9. ISSN: 1368-5031. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) A double-blind, randomized, controlled trial was carried out to evaluate the efficacy and safety of brimonidine, dorzolamide and latanoprost as an adjunctive therapy in patients with primary open angle glaucoma (POAG). A total of 200 males and 72 females with POAG uncontrolled with previous glaucoma therapy were randomly allocated to receive topical brimonidine 0.2% b.d. (n = 90), topical dorzolamide 2% b.d. (n = 91) or topical latanoprost 0.005% o.d. (n = 91). One year post treatment, the mean percentage redn. in intraocular pressure (IOP) between the three groups was statistically significant (p<0.0001). In an intergroup comparison of efficacy, there was a statistically significant difference between the brimonidine and dorzolamide groups (p=0.018) and between the dorzolamide and latanoprost groups (p=0.76) but the efficacy of brimonidine was not significantly higher than latanoprost in the brimonidine and latanoprost groups (p=0.002). Patients experiencing mild to severe side-effects were statistically similar in the three groups. On an inter-drug comparison of side-effects, we found no statistically significant difference in the brimonidine and latanoprost groups (p=0.25); and the brimonidine and dorzolamide groups (p=0.067), while the no. of side-effects with latanoprost was significantly higher in the dorzolamide and latanoprost groups (p<0.003). All three drugs caused a significant redn. in the mean IOP from pretreatment values. The brimonidine group had a higher no. of patients experiencing severe side-effects necessitating alteration of therapy. .

The effect of latanoprost 0

The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humor protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%. Diestelhorst, Michael; Roters, Sigrid; Krieglstein, Guenter K. ( Department of Ophthalmology, University of Cologne, Cologne D-50931, Germany). Graefe's Archive for Clinical and Experimental Ophthalmology, 235(1), 20-26 (English) 1997 Springer. CODEN: GACODL. ISSN: 0721-832X. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Latanoprost is a PGF2a analog which reduces the intraocular pressure (IOP) by increasing the uveoscleral outflow. The objective of this study was to investigate the effect of two different regimens of latanoprost on the diurnal IOP and also the effect of latanoprost on the blood-aq. barrier measured with a laser flare cell meter (Kowa FM-500). Moreover, the safety aspects of the two regimens regarding hyperemia were studied. A double-masked, randomized study was performed in 30 patients (9 males, 21 females; mean age 61.9 yr) with primary open-angle glaucoma or pseudoexfoliation glaucoma. Twenty patients were treated with latanoprost 0.0015% twice daily or 0.005% once daily for 3 wk in a cross-over design. Ten patients received timolol 0.5% twice daily as control. Latanoprost 0.005% once daily reduced IOP (± SEM) more effectively than latanoprost 0.0015% twice daily (9.8±0.9 mm Hg and 6.7±0.9 mm Hg, resp.). There was a statistically significant increase in the aq. humor protein concn. within the timolol group (P=0. 26839-75-8 and 130209-82-4 are cas registry numbers of chemicals which are used as reagents here.004), but not within the latanoprost group (P=0.97). There was no statistically significant difference in the change in aq. humor protein concn. from baseline between latanoprost and timolol groups (P=0.08). No statistically significant difference in conjunctival hyperemia between the two latanoprost regimens was found (P=0.37). Latanoprost 0.005% once daily reduced IOP more effectively than latanoprost 0.0015% twice daily (P<0.001). Latanoprost had no statistically or clin. significant effect on the blood-aq. barrier. There was no difference in hyperemia between the two regimens. Both concns. of latanoprost reduced IOP at least as well as timolol 0.5% eye drops. .